Trial Profile

A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of Tucatinib (MK-7119) in China Participants With HER2+ Advanced Breast Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucatinib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer
Focus Adverse reactions
Sponsors Merck Sharp & Dohme; Pfizer

20 Mar 2025 Planned End Date changed from 31 Mar 2025 to 31 Dec 2025.
20 Mar 2025 Planned primary completion date changed from 31 Mar 2025 to 31 Dec 2025.
12 Mar 2025 Planned End Date changed from 29 Dec 2025 to 31 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com